---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-019487"
form_type: "8-K"
ticker: "BTCY"
cik: "0001630113"
company_name: "BIOTRICITY INC."
filed_at: "2022-07-18T23:59:59+00:00"
generated_at: "2026-06-24T13:20:09.427432+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biotricity reports FY22 revenue $7.7M (+126% YoY); Q4 revenue $2.15M (+81%); net loss $30.2M

## Summary
- FY22 revenue $7.7M (+126% YoY); gross margin improved to 60% from 38% in FY21.
- Q4 FY22 revenue $2.15M (+81% YoY); gross margin 67% vs 60% in Q4 FY21.
- FY22 net loss $30.2M ($0.665 per share); adjusted loss per share $0.48.
- Cash $12M at March 31, 2022; closed $12M non-convertible debt and extinguished $1.6M legacy debt.
- Expanded network to 300+ centers, 1,500 cardiologists; launched Biotres, Bioheart, Biokit after FDA clearance.

## SEC filing metadata
- accession: 0001493152-22-019487
- form_type: 8-K
- ticker: BTCY
- cik: 0001630113
- company_name: BIOTRICITY INC.
- filed_at: 2022-07-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630113/000149315222019487/0001493152-22-019487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630113/000149315222019487/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-019487
- JSON: https://secwatch.observer/filing/0001493152-22-019487.json
- Plain text: https://secwatch.observer/filing/0001493152-22-019487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.